KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.68 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $385,200 | +7.0% | 40,000 | 0.0% | 0.33% | +21.5% |
| Q2 2023 | $360,000 | +114549.7% | 40,000 | 0.0% | 0.27% | +9.8% |
| Q1 2023 | $314 | +16.3% | 40,000 | 0.0% | 0.25% | +28.8% |
| Q4 2022 | $270 | -100.0% | 40,000 | 0.0% | 0.19% | -53.2% |
| Q3 2022 | $580,000 | +47.2% | 40,000 | 0.0% | 0.41% | +42.2% |
| Q2 2022 | $394,000 | -33.2% | 40,000 | 0.0% | 0.29% | -32.5% |
| Q1 2022 | $590,000 | +11.5% | 40,000 | 0.0% | 0.42% | +24.6% |
| Q4 2021 | $529,000 | -24.2% | 40,000 | 0.0% | 0.34% | -28.2% |
| Q3 2021 | $698,000 | -27.1% | 40,000 | 0.0% | 0.48% | -17.1% |
| Q2 2021 | $958,000 | -6.8% | 40,000 | 0.0% | 0.57% | -6.1% |
| Q1 2021 | $1,028,000 | +80.4% | 40,000 | +33.3% | 0.61% | +86.0% |
| Q4 2020 | $570,000 | -24.6% | 30,000 | -50.0% | 0.33% | +29.6% |
| Q3 2020 | $756,000 | +108.3% | 60,000 | +100.0% | 0.25% | +15.5% |
| Q2 2020 | $363,000 | +57.8% | 30,000 | 0.0% | 0.22% | +7.4% |
| Q1 2020 | $230,000 | -56.9% | 30,000 | 0.0% | 0.20% | -47.4% |
| Q4 2019 | $534,000 | +53.4% | 30,000 | 0.0% | 0.39% | +67.2% |
| Q3 2019 | $348,000 | – | 30,000 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
| TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
| VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
| TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
| Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
| Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
| GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
| DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
| Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |